シンポジウム2（II-S02）
Current Advance in Pediatric Interventional Cardiology; from Bench to Cath lab

[II-S02-05] Venus P Valve: From Bench to Cath Lab

^○Worakan Promphan (Department of Pediatric Cardiology Samitivej Sukhumvit Hospital Bangkok, Thailand)

Currently, percutaneous pulmonary valve implantation (PPVI) is considered an effective alternative treatment for conduit dysfunction. However, with limitations of the available valve diameters and the size of delivery systems, current exclusions of PPVI are dysfunctional large native RVOTs and body weight less than 30 kilograms. [1,2] A self-expandable platform of Venus P-valve (Venus Medtech, Shanghai, China) has been developed to overcome the RVOT limitation. A report from an experimental study has demonstrated excellent valve function after implantation [3]. First in man implantation has been published in 2014 with initial satisfactory results [4]. This valve can be securely implanted into large native RVOTs up to 32 millimeters in diameter. Although longevity of the Venus P valve is yet to be elucidated, a 6-month follow-up has shown excellent valve function. [5] In the near future, with continuous improvement of the valve design, PPVI shall become a standard treatment in most dysfunctional post-surgical RVOTs.